中英文说明丨艾美捷PD1抗体（BXC-BE0146）

上一篇 / 下一篇 2023-05-06 15:53:16/ 个人分类：生化试剂

PD-1/PD-L1 has become a research hotspot in tumor immunotherapy in recent years. Tumor cells recruit immunosuppressive cells and cytokines by overexpressing PD-1/PD-L1, reduce the Antigenicity of tumor cells, and tilt the balance of immune microenvironment from steady state to immunosuppression. This process is called immune editing.

Immune editing includes three processes: clearing, balancing, and escaping. Tumor cells ultimately evade the anti-tumor effects of the body's immune system through immune editing, forming clinically detectable tumors.

In recent years, research related to PD-1 antibodies has emerged, which may become a major anti-tumor tool.

Background of PD1 antibody (BXC-BE0146):

The InVivoMAb anti mouse PD-1 (CD279):

Research fields: cancer biology, immune checkpoint proteins, immunology;

Clone number: RMP1-14;

Antigen: PD-1;

Host source: rats;

Antibody subtype: IgG2a, κ；

Molecular weight: 150 kDa;

Recommended homotypic control: InVivoMAb anti mouse PD-1 (CD279) product number: BE0089;

Concentration: usually between 4 and 11 mg/ml depending on the batch;

Recommended dilution buffer: InVivoPure pH 7.0 dilution buffer, product number: IP0070;